These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33217774)

  • 1. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
    Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
    IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor agonists in cancer therapy.
    Adams S
    Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
    Federico S; Pozzetti L; Papa A; Carullo G; Gemma S; Butini S; Campiani G; Relitti N
    J Med Chem; 2020 Nov; 63(22):13466-13513. PubMed ID: 32845153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the development of Toll-like receptor (TLR) antagonists.
    Patra MC; Choi S
    Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
    Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
    Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications.
    Chen YH; Wu KH; Wu HP
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
    Mikulandra M; Pavelic J; Glavan TM
    Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Toll-like receptors with small molecule agents.
    Wang X; Smith C; Yin H
    Chem Soc Rev; 2013 Jun; 42(12):4859-66. PubMed ID: 23503527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptors: cost or benefit for cancer?
    Matijevic T; Pavelic J
    Curr Pharm Des; 2010; 16(9):1081-90. PubMed ID: 20030618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
    Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
    Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Responses with participation of toll-like receptors in protective immunity and in pathologic states].
    Skivka LM; Pozur VV
    Ukr Biokhim Zh (1999); 2008; 80(3):5-20. PubMed ID: 18959023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
    Shi M; Chen X; Ye K; Yao Y; Li Y
    Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
    Tartey S; Takeuchi O
    Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor modulators: a patent review (2006-2010).
    Basith S; Manavalan B; Lee G; Kim SG; Choi S
    Expert Opin Ther Pat; 2011 Jun; 21(6):927-44. PubMed ID: 21406035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Toll' gates for future immunotherapy.
    Ishii KJ; Uematsu S; Akira S
    Curr Pharm Des; 2006; 12(32):4135-42. PubMed ID: 17100616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immunity and cancer therapy.
    Maruyama K; Selmani Z; Ishii H; Yamaguchi K
    Int Immunopharmacol; 2011 Mar; 11(3):350-7. PubMed ID: 20955832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.
    Mukherjee S; Patra R; Behzadi P; Masotti A; Paolini A; Sarshar M
    Front Immunol; 2023; 14():1244345. PubMed ID: 37822929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.